Clinical trials: Neuroendocrine Cancer
Metastatic Melanoma
Radiotherapy & Combi in Metastatic Melanoma
The purpose of this study is to investigate the side effects and safety, and effectiveness of combining dabrafenib and trametinib with radiotherapy.
- Trial name
- CombiRT (NCT02392871)
- Testing
- Palliative radiotherapy, Dabrafenib and trametinib (combination)
- Where
- 3 sites in Australia
- Volunteers
- 10 people
- Sponsor
- Melanoma and Skin Cancer Trials Limited
Melanoma, Melanoma Stage III
CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma
Combination treatment with nivolumab and ipilimumab before surgery may help people with melanoma because the drugs are designed to help the immune system target and destroy cancer cells (immunotherapy), which may shrink the…
- Trial name
- NCT05289193
- Testing
- PET Scan, Nivolumab, Ipilimumab
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Cancer
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Cancer results from multiple mutations which cause cells to grow uncontrolled. It therefore may be necessary to inhibit several oncogenic targets to affect cancer cell growth.
- Trial name
- NCT01056601
- Testing
- Bortezomib, Panobinostat
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Melanoma, Immune Checkpoints Inhibitors
Biomarkers in Immunotherapy of Melanoma
Background: Immunotherapy has been successful in treating advanced melanoma, but a large proportion of patients do not respond to the treatment with immune checkpoint inhibitors (ICIs).
- Conditions
- Metastatic Melanoma, Immune Checkpoints Inhibitors, Gastrointestinal Microbiome (Bacterial and Viral), Exosomal mRNA Expression of PD-L1 and IFNγ
- Trial name
- NCT05878977
- Testing
- Immune checkpoint inhibitor
- Where
- Slovenia
- Volunteers
- 150 people
- Sponsor
- Institute of Oncology Ljubljana
Neuroendocrine Tumors
Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors
The purpose of this study is to verify if adding a locoregional treatment of liver metastasis (with trans-arterial embolization-TAE) to medical treatments of proven efficacy can prolong the progression free survival of patients…
- Trial name
- LOTUS (NCT01755182)
- Testing
- approved pharmacologic therapy, TAE
- Where
- 12 sites in Italy
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute, Naples
Merkel Cell Carcinoma
Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation
Primary objective: To estimate the efficacy of adjuvant nivolumab monotherapy in completely resected MCC patients Primary endpoint: Disease-free survival (DFS) rate evaluated at 12, 24 and 48 months after date of randomization…
- Trial name
- ADMEC-O (NCT02196961)
- Testing
- Nivolumab
- Where
- 20 sites in Germany, Netherlands
- Volunteers
- 180 people
- Sponsor
- Prof. Dr. med. Dirk Schadendorf
Neuroendocrine Tumors
Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel
The purpose of the study is to evaluate, in standard practice, the change in information received and perceived by the patient, extension of the disease and its treatment.
- Trial name
- OPERA (NCT03562091)
- Testing
- Data collection
- Where
- France
- Volunteers
- 115 people
- Sponsor
- Ipsen
Ewing Sarcoma, PEComa
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in…
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor
- Trial name
- NCT03190174
- Testing
- Nab-Rapamycin, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Melanoma
Review of the Literature and Serie of Patients Who Underwent Reconstruction After Wide Local Excision of Nail Apparatus for Melanoma
Melanomas of the nail bed are often diagnosed at the locally advanced stage. The standard treatment was amputation of the finger or toe, but it has now been established that enlarged excision of the nail plate is sufficient under…
- Trial name
- NCT06861023
- Testing
- Patients who have undergone extensive nail resection with reconstruction
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Melanoma; Renal Cell Carcinoma
Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma
The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may…
- Trial name
- NCT03728842
- Testing
- Blood collection for laboratory studies, Data collection from medical record
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Indiana University
Metastatic Melanoma, Renal Cell Cancer
Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer
Background: -Although IL-2 can shrink tumors in about 20 percent of patients with metastatic kidney cancer and in 15 percent of patients with metastatic melanoma, it is not fully known how the drug works.
- Trial name
- NCT00304460
- Testing
- aldesleukin
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Thyroid Neoplasia, Well-Differentiated Thyroid Cancer
Thermal Ablation of Cervical Metastases From Thyroid Carcinoma
This study will evaluate the clinical response and safety of ultrasound guided percutaneous thermal ablation of lymph node metastases from thyroid carcinoma as an alternative to surgical treatment.
- Conditions
- Thyroid Neoplasia, Well-Differentiated Thyroid Cancer, Medullary Thyroid Cancer, Lymph Node Metastases
- Trial name
- NCT04522570
- Testing
- Laser ablation, Cryoablation, Radiofrequency ablation
- Where
- Brazil
- Volunteers
- 84 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Thymic Epithelial Tumor, Teratoma
Establishing Prospective Mediastinal Tumor Database of PUMCH
This study aims to prospectively document the population characteristics, imaging findings, pathological features, prognostic factors, etc., of patients with mediastinal tumors.
- Conditions
- Thymic Epithelial Tumor, Teratoma, Thymic Cyst, Retrosternal Goitre
- Trial name
- MTDPUMCH (NCT06421805)
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Peking Union Medical College Hospital
Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors.
- Conditions
- Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8
- Trial name
- NCT05040360
- Testing
- Capecitabine, Temozolomide
- Where
- 448 sites in United States, Mexico and 1 more
- Volunteers
- 141 people
- Sponsor
- SWOG Cancer Research Network
Schwannoma, Vestibular, Neurofibromatosis 2
NF2 Natural History Consortium
OBJECTIVES: I. Define the growth rates and clinical course of NF2-related tumors in patients with neurofibromatosis type 2. Associate growth rate with physical function.
- Conditions
- Schwannoma, Vestibular, Neurofibromatosis 2, Meningioma
- Trial name
- NCT00004483
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- House Ear Institute
Advanced Cancer, Melanoma
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced…
- Conditions
- Advanced Cancer, Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT02658890
- Testing
- BMS-986205, Nivolumab, Ipilimumab
- Where
- 47 sites in United States, Australia and 9 more
- Volunteers
- 627 people
- Sponsor
- Bristol-Myers Squibb
Paraganglioma, Pheochromocytoma
Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study
Phaeochromocytomas and paragangliomas (PPGLs) are tumours of the adrenal medulla and extra-adrenal sympathetic nervous system, some which can become metastatic. It is a very rare disease and the tumours are often detected late.
- Conditions
- Paraganglioma, Pheochromocytoma, Genetic Predisposition to Disease, Pathology
- Trial name
- PPGL-Pred (NCT04788927)
- Where
- 2 sites in Denmark
- Volunteers
- 400 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Melanoma, Unsatisfied Needs
Holistic Needs Assessments in Patients With Melanoma
This study will assess whether a needs assessment/management intervention for patients with malignant melanoma is achievable, reasonable, realistic and of value to patients with malignant melanoma and health professionals…
- Trial name
- NCT06189261
- Testing
- Holistic needs assessment based on the use of patient-reported outcome measures
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Surrey